Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 34 Issue 3
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2016  >  34(3): 219-222,274

SUN Guoquan, SHU Lixin, WANG Xiaojuan, CHEN Shengxin, YANG Zhangwei, LI Jiewei. Study on the use of antimicrobial agents in hospitalized trauma patients based on medical big data[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 466-471. doi: 10.3969/j.issn.1006-0111.2017.05.021
Citation: JIANG Wenli, HUANG Caiguo. Wentilactone A inhibition of migration of small cell lung carcinoma NCI-H1688 cell line[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(3): 219-222,274. doi: 10.3969/j.issn.1006-0111.2016.03.007
shu

Wentilactone A inhibition of migration of small cell lung carcinoma NCI-H1688 cell line

doi: 10.3969/j.issn.1006-0111.2016.03.007

  • Department of Biochemistry and Molecular Biology, Faculty of Basic Medicine, Second Military Medical University, Shanghai 200433, China

  • Received Date: 2016-01-27
  • Rev Recd Date: 2016-03-31
  • Objective To investigate mechanism of Wentilactone A (WA) inhibition of small cell lung cancer(SCLC) cell line NCI-H1688 migration. Methods The migration and proliferation were analyzed by wounding-healing assay and MTT assay[3- (4, 5-Dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide, MTT]. Immunofluorescence was used to confirm the expression of ATF3 protein after WA treatment. Western blot was used to examine the expression of key proteins in ATF3/Nrf2/AKR1C1 signal pathway. Results WA inhibits the proliferation and migration of SCLC. MTT analysis showed WA inhibits the proliferation of NCI-H1688 cell line in a time-dependent manner. The number of migrated cells in WA treatment group was (8.73±1.06) mm, which was lower than that of control group (15.63±3.11) mm, The number of migrated cells in AKR1C1 expression group was (24.37±0.90) mm, the number of migrated cells in AKR1C1 expression and WA treatment group was (14.17±1.31) mm, with significant difference (P<0.05). WA enhances the nuclear expression of ATF3, and then reduces the expression of p-Nrf2 and AKR1C1. Conclusion WA inhibits the proliferation and migration of SCLC through ATF3/Nrf2/AKR1C1 signal pathway.
  • [1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
    [2] Chen W, Zheng R, Zhang S, et al. Report of cancer incidence and mortality in China, 2010[J]. Ann Transl Med, 2014, 2(7):61.
    [3] Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer[J]. Cancer Invest, 2011,29(4):325-337.
    [4] Modesto JL, Hull A, Angstadt AY, et al. NNK reduction pathway gene polymorphisms and risk of lung cancer[J]. Mol Carcinog, 2015, 54(Suppl 1):E94-E102.
    [5] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016,66(1):7-30.
    [6] Stinchcombe TE,Gore EM, Limited-stage small cell lung cancer:current chemoradiotherapy treatment paradigms[J]. Oncologist, 2010,15(2):187-195.
    [7] Johnson BE. Management of small cell lung cancer[J]. Clin Chest Med, 2002,23(1):225-239.
    [8] Traven K, Sinreih M, Stojan J, et al. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3[J]. Chem Biol Interact, 2015, 234:349-359.
    [9] Stefane B, Brozic P, Vehovc M, et al. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3[J]. Eur J Med Chem, 2009,44(6):2563-2571.
    [10] Penning TM. The aldo-keto reductases (AKRs):Overview[J]. Chem Biol Interact, 2015,234:236-246.
    [11] Rizner TL, Penning TM. Role of aldo-keto reductase family 1(AKR1) enzymes in human steroid metabolism[J]. Steroids, 2014,79:49-63.
    [12] Haddad SA, Lunetta KL, Ruiz-Narváez EA, et al. Hormone-related pathways and risk of breast cancer subtypes in African American women[J]. Breast Cancer Res Treat, 2015,154(1):145-154.
    [13] Naumann JM, Messinger J, Bureik M. Human 20alpha-hydroxysteroid dehydrogenase (AKR1C1)-dependent biotransformation with recombinant fission yeast Schizosaccharomyces pombe[J]. J Biotechnol, 2010,150(1):161-170.
    [14] Byrns MC, Jin Y, Penning TM. Inhibitors of type 517beta-hydroxysteroid dehydrogenase (AKR1C3):overview and structural insights[J]. J Steroid Biochem Mol Biol, 2011,125(1-2):95-104.
    [15] Matsunaga T, Hojo A, Yamane Y, et al. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers[J]. Chem Biol Interact, 2013,202(1-3):234-242.
    [16] Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression[J]. Free Radic Biol Med, 2004,36(10):1199-1207.
    [17] Nishinaka T, Miura T, Okumura M, et al. Regulation of aldo-keto reductase AKR1B10 gene expression:involvement of transcription factor Nrf2[J]. Chem Biol Interact, 2011,191(1-3):185-191.
    [18] Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2(Keap1) signaling in oxidative stress[J]. Free Radic Biol Med, 2009,47(9):1304-1309.
    [19] Cheng X, Ku CH, Siow RC. Regulation of the Nrf2 antioxidant pathway by microRNAs:New players in micromanaging redox homeostasis[J]. Free Radic Biol Med, 2013,64:4-11.
    [20] Brown SL, Sekhar KR, Rachakonda G, et al. Activating transcription factor 3 is a novel repressor of the nuclear factor erythroid-derived 2-related factor 2(Nrf2)-regulated stress pathway[J]. Cancer Res, 2008,68(2):364-368.
    [21] 田鹤,姜文丽,楼国良,等.AKR1C1在非小细胞肺癌的表达及功能分析[J].临床肿瘤学杂志,2015,20(6):487-491.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0400.511.522.5Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 89.9 %FULLTEXT: 89.9 %META: 8.5 %META: 8.5 %PDF: 1.6 %PDF: 1.6 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 27.7 %其他: 27.7 %Australia: 0.5 %Australia: 0.5 %China: 0.5 %China: 0.5 %United States: 0.3 %United States: 0.3 %[]: 0.3 %[]: 0.3 %上海: 2.2 %上海: 2.2 %临汾: 0.5 %临汾: 0.5 %北京: 11.5 %北京: 11.5 %合肥: 0.3 %合肥: 0.3 %天津: 0.3 %天津: 0.3 %广州: 0.3 %广州: 0.3 %张家口: 2.2 %张家口: 2.2 %惠州: 0.3 %惠州: 0.3 %成都: 0.3 %成都: 0.3 %杭州: 0.8 %杭州: 0.8 %武汉: 0.3 %武汉: 0.3 %泉州: 0.3 %泉州: 0.3 %洛阳: 0.3 %洛阳: 0.3 %秦皇岛: 0.5 %秦皇岛: 0.5 %芒廷维尤: 30.7 %芒廷维尤: 30.7 %西宁: 16.2 %西宁: 16.2 %赤峰: 0.3 %赤峰: 0.3 %运城: 1.1 %运城: 1.1 %镇江: 0.3 %镇江: 0.3 %长沙: 0.3 %长沙: 0.3 %长治: 0.3 %长治: 0.3 %黄冈: 1.6 %黄冈: 1.6 %其他AustraliaChinaUnited States[]上海临汾北京合肥天津广州张家口惠州成都杭州武汉泉州洛阳秦皇岛芒廷维尤西宁赤峰运城镇江长沙长治黄冈Highcharts.com

  • Cited by

    Periodical cited type(9)

    1. 强卫平，官蜀钧. 浅析“保胃气”理论在防治脑出血并发症中的临床意义. 陕西中医药大学学报. 2022(02): 53-56 .
    2. 刘洪涛，冯守宁，董梁. 雷尼替丁联合奥美拉唑治疗重度颅脑损伤并发上消化道出血患者的效果观察. 华夏医学. 2022(02): 1-5 .
    3. 王琤毓，陈明红. 基于药物经济学研究的方法对质子泵抑制剂预防重型颅脑损伤患者应激性溃疡的分析. 海峡药学. 2020(09): 151-153 .
    4. 高慧，杨洁，胡云霞，陈秋华，鲁俊，王醒，陈明祺. 升降散对重型颅脑损伤患者胃肠功能障碍及预后影响的临床研究. 中国中医急症. 2019(04): 565-567+571 .
    5. 白荷荷，聂晓静，王园姬. 2014—2016年西安市中心医院质子泵抑制剂的使用情况分析. 现代药物与临床. 2018(07): 1814-1819 .
    6. 陈向荣，杜菊梅，张磊，吴宗涛，徐东泽. 三七白及散对基底节区、丘脑出血患者胃黏膜灌注及应激性溃疡发生率的影响. 中医药导报. 2018(18): 96-98 .
    7. 李鹏，刘建萍，黄雪英. 奥美拉唑不同给药方案预防重型颅脑损伤应激性溃疡的疗效评价. 江西医药. 2016(08): 792-793 .
    8. 巩莉. 质子泵抑制剂诱发感染危险性研究进展. 山西医药杂志. 2016(14): 1659-1660 .
    9. 孙会芳. 重症监护病房重型颅脑损伤患者继发肺部感染的相关因素分析. 中国药物经济学. 2016(06): 127-129 .

    Other cited types(3)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4049) PDF downloads(12) Cited by(12)

Related
Proportional views

Wentilactone A inhibition of migration of small cell lung carcinoma NCI-H1688 cell line

doi: 10.3969/j.issn.1006-0111.2016.03.007
  • Department of Biochemistry and Molecular Biology, Faculty of Basic Medicine, Second Military Medical University, Shanghai 200433, China
  • Received Date: 2016-01-27
  • Rev Recd Date: 2016-03-31

Abstract: Objective To investigate mechanism of Wentilactone A (WA) inhibition of small cell lung cancer(SCLC) cell line NCI-H1688 migration. Methods The migration and proliferation were analyzed by wounding-healing assay and MTT assay[3- (4, 5-Dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide, MTT]. Immunofluorescence was used to confirm the expression of ATF3 protein after WA treatment. Western blot was used to examine the expression of key proteins in ATF3/Nrf2/AKR1C1 signal pathway. Results WA inhibits the proliferation and migration of SCLC. MTT analysis showed WA inhibits the proliferation of NCI-H1688 cell line in a time-dependent manner. The number of migrated cells in WA treatment group was (8.73±1.06) mm, which was lower than that of control group (15.63±3.11) mm, The number of migrated cells in AKR1C1 expression group was (24.37±0.90) mm, the number of migrated cells in AKR1C1 expression and WA treatment group was (14.17±1.31) mm, with significant difference (P<0.05). WA enhances the nuclear expression of ATF3, and then reduces the expression of p-Nrf2 and AKR1C1. Conclusion WA inhibits the proliferation and migration of SCLC through ATF3/Nrf2/AKR1C1 signal pathway.

SUN Guoquan, SHU Lixin, WANG Xiaojuan, CHEN Shengxin, YANG Zhangwei, LI Jiewei. Study on the use of antimicrobial agents in hospitalized trauma patients based on medical big data[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 466-471. doi: 10.3969/j.issn.1006-0111.2017.05.021
Citation: JIANG Wenli, HUANG Caiguo. Wentilactone A inhibition of migration of small cell lung carcinoma NCI-H1688 cell line[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(3): 219-222,274. doi: 10.3969/j.issn.1006-0111.2016.03.007
shu

    HTML

Reference (21)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return